ClearPoint Neuro, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ClearPoint Neuro, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-25.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 60% of Healthcare companies in United States.
Cash Locked Ratio
$37For every $100 of sales, $37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $57 tied up three years earlier.
More money tied up than 78% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$55Sales grew 80% in 3 years, but profit fell: $55 less profit per $100 of extra sales.
Lower than 83% of Healthcare companies in United States.
Asset Productivity Ratio
+80% / +76%In 3 years sales changed by +80% while total assets changed by +76%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
-34.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 66% of Healthcare companies in United States.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 73% of Healthcare companies in United States.
Tangible Assets Ratio
78%Of every $100 the company owns, $78 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 54% of Healthcare companies in United States.
Tangible Net Worth Ratio
24%Of every $100 of net worth, $24 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 64% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
ClearPoint Neuro, Inc. made a loss over the last year. ClearPoint Neuro, Inc. owes $0.88 for every $1 it owns. ClearPoint Neuro, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossClearPoint Neuro, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
26.18The share price is 26.18 times ClearPoint Neuro, Inc.'s book value per share, higher than 95% of Healthcare companies in United States.
Market cap
$282 MThe total market value of all of ClearPoint Neuro, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$11 MWhat ClearPoint Neuro, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.35Net worth divided by the number of shares. The share price of $9.25 is 26.2 times this, which is the P/B above.
Return on equity (ROE)
-226.5%ClearPoint Neuro, Inc. lost 226.5% of its shareholders' money over the last year, lower than 86% of Healthcare companies in United States.
Owes vs Owns
0.88×ClearPoint Neuro, Inc. owes $0.88 for every $1 it owns (high), higher than 81% of Healthcare companies in United States.
Dividend yield
NoneClearPoint Neuro, Inc. does not currently pay a dividend.
Revenue growth
+18%Revenue rose 18% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Profit growth
LossClearPoint Neuro, Inc. made a loss in each of the last two years.
Profit margin
-69.1%ClearPoint Neuro, Inc. lost $69 for every $100 of revenue.
Interest cover
Not coveredClearPoint Neuro, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtClearPoint Neuro, Inc. had $12 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ClearPoint Neuro, Inc.: $282 M ÷ $11 M (30 Jun 2026) = 26.2.
What is ClearPoint Neuro, Inc.'s return on equity?
ClearPoint Neuro, Inc. lost 226.5% of its shareholders' money over the last year, lower than 86% of Healthcare companies in United States.
How much does ClearPoint Neuro, Inc. owe compared with what it owns?
ClearPoint Neuro, Inc. owes $0.88 for every $1 it owns (high), higher than 81% of Healthcare companies in United States.
Does ClearPoint Neuro, Inc. pay a dividend?
No. ClearPoint Neuro, Inc. does not currently pay a dividend.
Is ClearPoint Neuro, Inc.'s revenue growing?
Revenue rose 18% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.